Natural Product (NP) Details
| General Information of the NP (ID: NP0551) | |||||
|---|---|---|---|---|---|
| Name |
Oridonin
|
||||
| Synonyms |
Oridonin; 28957-04-2; ISODONOL; Oridonine; UNII-0APJ98UCLQ; Rubescensin A; 0APJ98UCLQ; Rubescensin; Oridonin A; Kaur-16-en-15-one, 7,20-epoxy-1,6,7,14-tetrahydroxy-, (1alpha,6beta,7alpha,14R)-; NSC 250682; Curator_000006; CHEMBL1164920; SCHEMBL19217133; CHEBI:138236; HY-N0004; ZINC12661785; (14R)-7-alpha,20-Epoxy-1-alpha,6-beta,7,14-tetrahydroxykaur-16-en-15-one; AKOS025310967; CCG-208386; (1-alpha,6-beta,7-alpha,14R)-7,20-Epoxy-1,6,7,14-tetrahydroxykaur-16-en-15-one; AS-15421; P269; AB0016908; CS-0007086; 957O042; Q27236543; 7?,20-Epoxy-1?,6?,7,14-tetrahydroxykaur-16-en-15-one; (1alpha,6beta,7alpha,14R)-7,20-epoxy-1,6,7,14-tetrahydroxykaur-16-en-15-one; Kaur-16-en-15-one, 7,20-epoxy-1,6,7,14-tetrahydroxy-, (1a,6b,7a,14R)-; KAUR-16-EN-15-ONE, 7-alpha,20-EPOXY-1-alpha,6-beta,7,14-TETRAHYDROXY-, (14R)-; (1alpha,5beta,6beta,7alpha,8alpha,9beta,10alpha,13alpha,14R)-1,6,7,14-tetrahydroxy-7,20-epoxykaur-16-en-15-one; (1S,2S,5S,8R,9S,10S,11R,15S,18R)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one
Click to Show/Hide
|
||||
| Species Origin | Isodon rubescens ... | Click to Show/Hide | |||
| Isodon rubescens | |||||
| Disease | Stomach cancer [ICD-11: 2B72] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.59
MDCK Permeability
-4.968
PAMPA
+++
HIA
+++
Distribution
VDss
-0.206
PPB
48.3%
BBB
- - -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
- - -
CYP2C9 inhibitor
- - -
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
- - -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
- - -
HLM Stability
- - -
Excretion
CLplasma
4.581
T1/2
2.562
Toxicity
DILI
- -
Rat Oral Acute Toxicity
+
FDAMDD
+
Respiratory
++
Human Hepatotoxicity
-
Ototoxicity
+
Drug-induced Nephrotoxicity
++
Drug-induced Neurotoxicity
- -
Hematotoxicity
- -
Genotoxicity
+
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C20H28O6
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC1(CCC(C23C1C(C(C45C2CCC(C4O)C(=C)C5=O)(OC3)O)O)O)C
|
||||
| InChI |
1S/C20H28O6/c1-9-10-4-5-11-18-8-26-20(25,19(11,14(9)22)15(10)23)16(24)13(18)17(2,3)7-6-12(18)21/h10-13,15-16,21,23-25H,1,4-8H2,2-3H3/t10-,11-,12-,13+,15+,16-,18+,19-,20+/m0/s1
|
||||
| InChIKey |
SDHTXBWLVGWJFT-XKCURVIJSA-N
|
||||
| CAS Number |
CAS 28957-04-2
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Cetuximab | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BECN1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PRKAA2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | PRKAA2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HEp-2 | CVCL_1906 | Laryngeal carcinoma | Homo sapiens | ||
| Tu 212 | CVCL_4915 | Head and neck squamous cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Autophagy might be strongly associated with the antitumor efficacy of ORI/Cet, which may be beneficial to the clinical application of ORI/Cet in LSCC treatment ORI/Cet in LSCC treatment. | |||||
| Imatinib | Mantle cell lymphoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | c-RAF | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | JTK8 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MEK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | STAT5B | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SUP-B15 | CVCL_0103 | B acute lymphoblastic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Caterpiller protein 1.1 (NLRP3) | Molecule Info | [4] | |
| CDK-interacting protein 1 (CDKN1A) | Molecule Info | [5] | ||
| DNA-binding factor KBF1 (p105) | Molecule Info | [4] | ||
| Fatty acid synthase (FASN) | Molecule Info | [6] | ||
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Molecule Info | [4] | ||
| PPAR-gamma (PPARG) | Molecule Info | [7] | ||
| Protein kinase B alpha (AKT1) | Molecule Info | [5] | ||
| Transcription factor MafG (IFRD1) | Molecule Info | [8] | ||
| BioCyc | Fatty acid biosynthesis initiation | Click to Show/Hide | ||
| 2 | Fatty acid elongation -- saturated | |||
| 3 | Palmitate biosynthesis | |||
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | ErbB signaling pathway | |||
| 3 | Ras signaling pathway | |||
| 4 | Rap1 signaling pathway | |||
| 5 | cGMP-PKG signaling pathway | |||
| 6 | cAMP signaling pathway | |||
| 7 | Chemokine signaling pathway | |||
| 8 | HIF-1 signaling pathway | |||
| 9 | FoxO signaling pathway | |||
| 10 | Sphingolipid signaling pathway | |||
| 11 | mTOR signaling pathway | |||
| 12 | PI3K-Akt signaling pathway | |||
| 13 | AMPK signaling pathway | |||
| 14 | Apoptosis | |||
| 15 | Adrenergic signaling in cardiomyocytes | |||
| 16 | VEGF signaling pathway | |||
| 17 | Osteoclast differentiation | |||
| 18 | Focal adhesion | |||
| 19 | Tight junction | |||
| 20 | Signaling pathways regulating pluripotency of stem cells | |||
| 21 | Platelet activation | |||
| 22 | Toll-like receptor signaling pathway | |||
| 23 | Jak-STAT signaling pathway | |||
| 24 | T cell receptor signaling pathway | |||
| 25 | B cell receptor signaling pathway | |||
| 26 | Fc epsilon RI signaling pathway | |||
| 27 | Fc gamma R-mediated phagocytosis | |||
| 28 | TNF signaling pathway | |||
| 29 | Neurotrophin signaling pathway | |||
| 30 | Cholinergic synapse | |||
| 31 | Dopaminergic synapse | |||
| 32 | Insulin signaling pathway | |||
| 33 | Progesterone-mediated oocyte maturation | |||
| 34 | Estrogen signaling pathway | |||
| 35 | Prolactin signaling pathway | |||
| 36 | Thyroid hormone signaling pathway | |||
| 37 | Adipocytokine signaling pathway | |||
| 38 | Glucagon signaling pathway | |||
| 39 | Regulation of lipolysis in adipocytes | |||
| 40 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 41 | Carbohydrate digestion and absorption | |||
| 42 | Chagas disease (American trypanosomiasis) | |||
| 43 | Toxoplasmosis | |||
| 44 | Tuberculosis | |||
| 45 | Hepatitis C | |||
| 46 | Hepatitis B | |||
| 47 | Measles | |||
| 48 | Influenza A | |||
| 49 | HTLV-I infection | |||
| 50 | Epstein-Barr virus infection | |||
| 51 | Pathways in cancer | |||
| 52 | Proteoglycans in cancer | |||
| 53 | Colorectal cancer | |||
| 54 | Renal cell carcinoma | |||
| 55 | Pancreatic cancer | |||
| 56 | Endometrial cancer | |||
| 57 | Glioma | |||
| 58 | Prostate cancer | |||
| 59 | Melanoma | |||
| 60 | Chronic myeloid leukemia | |||
| 61 | Acute myeloid leukemia | |||
| 62 | Small cell lung cancer | |||
| 63 | Non-small cell lung cancer | |||
| 64 | Central carbon metabolism in cancer | |||
| 65 | Choline metabolism in cancer | |||
| 66 | Protein processing in endoplasmic reticulum | |||
| 67 | Fatty acid biosynthesis | |||
| 68 | Metabolic pathways | |||
| 69 | Fatty acid metabolism | |||
| 70 | PPAR signaling pathway | |||
| 71 | Huntington's disease | |||
| 72 | Transcriptional misregulation in cancer | |||
| 73 | Thyroid cancer | |||
| 74 | NF-kappa B signaling pathway | |||
| 75 | NOD-like receptor signaling pathway | |||
| 76 | RIG-I-like receptor signaling pathway | |||
| 77 | Cytosolic DNA-sensing pathway | |||
| 78 | Cocaine addiction | |||
| 79 | Epithelial cell signaling in Helicobacter pylori infection | |||
| 80 | Shigellosis | |||
| 81 | Salmonella infection | |||
| 82 | Pertussis | |||
| 83 | Legionellosis | |||
| 84 | Leishmaniasis | |||
| 85 | Amoebiasis | |||
| 86 | Herpes simplex infection | |||
| 87 | Viral carcinogenesis | |||
| 88 | MicroRNAs in cancer | |||
| 89 | Inflammatory bowel disease (IBD) | |||
| NetPath Pathway | TSH Signaling Pathway | Click to Show/Hide | ||
| 2 | IL5 Signaling Pathway | |||
| 3 | IL1 Signaling Pathway | |||
| 4 | TGF_beta_Receptor Signaling Pathway | |||
| 5 | Leptin Signaling Pathway | |||
| 6 | TCR Signaling Pathway | |||
| 7 | IL2 Signaling Pathway | |||
| 8 | TNFalpha Signaling Pathway | |||
| Panther Pathway | Angiogenesis | Click to Show/Hide | ||
| 2 | Apoptosis signaling pathway | |||
| 3 | EGF receptor signaling pathway | |||
| 4 | Endothelin signaling pathway | |||
| 5 | FGF signaling pathway | |||
| 6 | Huntington disease | |||
| 7 | Hypoxia response via HIF activation | |||
| 8 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| 9 | Insulin/IGF pathway-protein kinase B signaling cascade | |||
| 10 | Interleukin signaling pathway | |||
| 11 | PI3 kinase pathway | |||
| 12 | T cell activation | |||
| 13 | VEGF signaling pathway | |||
| 14 | p53 pathway | |||
| 15 | Ras Pathway | |||
| 16 | p53 pathway by glucose deprivation | |||
| 17 | p53 pathway feedback loops 2 | |||
| 18 | CCKR signaling map ST | |||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
| 2 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
| 3 | Fc Epsilon Receptor I Signaling in Mast Cells | |||
| 4 | Insulin Signalling | |||
| 5 | Leucine Stimulation on Insulin Signaling | |||
| 6 | Fatty Acid Biosynthesis | |||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
| 2 | Fc-epsilon receptor I signaling in mast cells | |||
| 3 | Endothelins | |||
| 4 | BCR signaling pathway | |||
| 5 | LPA receptor mediated events | |||
| 6 | Insulin Pathway | |||
| 7 | IL4-mediated signaling events | |||
| 8 | TCR signaling in naï | |||
| 9 | ||||
| 10 | Plasma membrane estrogen receptor signaling | |||
| 11 | CD40/CD40L signaling | |||
| 12 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
| 13 | Signaling events mediated by PTP1B | |||
| 14 | S1P3 pathway | |||
| 15 | Coregulation of Androgen receptor activity | |||
| 16 | Reelin signaling pathway | |||
| 17 | Integrin-linked kinase signaling | |||
| 18 | TCR signaling in naï | |||
| 19 | ||||
| 20 | Angiopoietin receptor Tie2-mediated signaling | |||
| 21 | FAS (CD95) signaling pathway | |||
| 22 | Thromboxane A2 receptor signaling | |||
| 23 | Regulation of Telomerase | |||
| 24 | FOXA2 and FOXA3 transcription factor networks | |||
| 25 | Glucocorticoid receptor regulatory network | |||
| 26 | mTOR signaling pathway | |||
| 27 | CXCR4-mediated signaling events | |||
| 28 | IGF1 pathway | |||
| 29 | FoxO family signaling | |||
| 30 | IL2 signaling events mediated by PI3K | |||
| 31 | Ceramide signaling pathway | |||
| 32 | p75(NTR)-mediated signaling | |||
| 33 | E-cadherin signaling in the nascent adherens junction | |||
| 34 | amb2 Integrin signaling | |||
| 35 | Integrins in angiogenesis | |||
| 36 | IFN-gamma pathway | |||
| 37 | ErbB1 downstream signaling | |||
| 38 | ErbB2/ErbB3 signaling events | |||
| 39 | IL6-mediated signaling events | |||
| 40 | E-cadherin signaling in keratinocytes | |||
| 41 | Nephrin/Neph1 signaling in the kidney podocyte | |||
| 42 | Retinoic acid receptors-mediated signaling | |||
| 43 | IL8- and CXCR2-mediated signaling events | |||
| 44 | Signaling events mediated by the Hedgehog family | |||
| 45 | Nongenotropic Androgen signaling | |||
| 46 | Hedgehog signaling events mediated by Gli proteins | |||
| 47 | Caspase Cascade in Apoptosis | |||
| 48 | CXCR3-mediated signaling events | |||
| 49 | VEGFR1 specific signals | |||
| 50 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| 51 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
| 52 | a6b1 and a6b4 Integrin signaling | |||
| 53 | Aurora A signaling | |||
| 54 | Insulin-mediated glucose transport | |||
| 55 | Class I PI3K signaling events mediated by Akt | |||
| 56 | IL8- and CXCR1-mediated signaling events | |||
| 57 | HIF-1-alpha transcription factor network | |||
| 58 | p53 pathway | |||
| 59 | Trk receptor signaling mediated by PI3K and PLC-gamma | |||
| 60 | VEGFR3 signaling in lymphatic endothelium | |||
| 61 | FGF signaling pathway | |||
| 62 | p73 transcription factor network | |||
| 63 | Validated transcriptional targets of deltaNp63 isoforms | |||
| 64 | Noncanonical Wnt signaling pathway | |||
| 65 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| 66 | Signaling events mediated by HDAC Class I | |||
| 67 | RXR and RAR heterodimerization with other nuclear receptor | |||
| 68 | Regulation of retinoblastoma protein | |||
| 69 | Atypical NF-kappaB pathway | |||
| 70 | Canonical NF-kappaB pathway | |||
| 71 | IL12-mediated signaling events | |||
| 72 | Alternative NF-kappaB pathway | |||
| 73 | Osteopontin-mediated events | |||
| 74 | IL1-mediated signaling events | |||
| 75 | TNF receptor signaling pathway | |||
| 76 | IL23-mediated signaling events | |||
| 77 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
| 78 | EPO signaling pathway | |||
| Reactome | Activation of BAD and translocation to mitochondria | Click to Show/Hide | ||
| 2 | GPVI-mediated activation cascade | |||
| 3 | PIP3 activates AKT signaling | |||
| 4 | Translocation of GLUT4 to the plasma membrane | |||
| 5 | Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |||
| 6 | AKT phosphorylates targets in the cytosol | |||
| 7 | AKT phosphorylates targets in the nucleus | |||
| 8 | Negative regulation of the PI3K/AKT network | |||
| 9 | eNOS activation | |||
| 10 | AKT-mediated inactivation of FOXO1A | |||
| 11 | Integrin alphaIIb beta3 signaling | |||
| 12 | Deactivation of the beta-catenin transactivating complex | |||
| 13 | CD28 dependent PI3K/Akt signaling | |||
| 14 | CTLA4 inhibitory signaling | |||
| 15 | G beta:gamma signalling through PI3Kgamma | |||
| 16 | KSRP (KHSRP) binds and destabilizes mRNA | |||
| 17 | VEGFR2 mediated vascular permeability | |||
| 18 | TP53 Regulates Metabolic Genes | |||
| 19 | Constitutive Signaling by AKT1 E17K in Cancer | |||
| 20 | ChREBP activates metabolic gene expression | |||
| 21 | Activation of gene expression by SREBF (SREBP) | |||
| 22 | Fatty Acyl-CoA Biosynthesis | |||
| 23 | PPARA activates gene expression | |||
| 24 | Transcriptional regulation of white adipocyte differentiation | |||
| 25 | Nuclear Receptor transcription pathway | |||
| 26 | Activation of NF-kappaB in B cells | |||
| 27 | RIP-mediated NFkB activation via ZBP1 | |||
| 28 | Regulated proteolysis of p75NTR | |||
| 29 | NF-kB is activated and signals survival | |||
| 30 | Senescence-Associated Secretory Phenotype (SASP) | |||
| 31 | FCERI mediated NF-kB activation | |||
| 32 | DEx/H-box helicases activate type I IFN and inflammatory cytokines production | |||
| 33 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
| 34 | Interleukin-1 processing | |||
| 35 | IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | |||
| 36 | IkBA variant leads to EDA-ID | |||
| 37 | CLEC7A (Dectin-1) signaling | |||
| 38 | CD209 (DC-SIGN) signaling | |||
| 39 | CLEC7A/inflammasome pathway | |||
| 40 | MAP3K8 (TPL2)-dependent MAPK1/3 activation | |||
| 41 | TRAF6 mediated NF-kB activation | |||
| WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
| 2 | DNA Damage Response (only ATM dependent) | |||
| 3 | TCR Signaling Pathway | |||
| 4 | Notch Signaling Pathway | |||
| 5 | EPO Receptor Signaling | |||
| 6 | IL-2 Signaling Pathway | |||
| 7 | Insulin Signaling | |||
| 8 | Endochondral Ossification | |||
| 9 | EGF/EGFR Signaling Pathway | |||
| 10 | IL-4 Signaling Pathway | |||
| 11 | TGF beta Signaling Pathway | |||
| 12 | IL-6 signaling pathway | |||
| 13 | Wnt Signaling Pathway Netpath | |||
| 14 | Copper homeostasis | |||
| 15 | Extracellular vesicle-mediated signaling in recipient cells | |||
| 16 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
| 17 | IL-3 Signaling Pathway | |||
| 18 | Cardiac Hypertrophic Response | |||
| 19 | Translocation of GLUT4 to the Plasma Membrane | |||
| 20 | Regulation of mRNA Stability by Proteins that Bind AU-rich Elements | |||
| 21 | PIP3 activates AKT signaling | |||
| 22 | Signal Transduction of S1P Receptor | |||
| 23 | T-Cell Receptor and Co-stimulatory Signaling | |||
| 24 | Primary Focal Segmental Glomerulosclerosis FSGS | |||
| 25 | Apoptosis | |||
| 26 | Alpha 6 Beta 4 signaling pathway | |||
| 27 | BDNF signaling pathway | |||
| 28 | Integrated Pancreatic Cancer Pathway | |||
| 29 | Oncostatin M Signaling Pathway | |||
| 30 | Corticotropin-releasing hormone | |||
| 31 | Interleukin-11 Signaling Pathway | |||
| 32 | AGE/RAGE pathway | |||
| 33 | TNF alpha Signaling Pathway | |||
| 34 | B Cell Receptor Signaling Pathway | |||
| 35 | Prostate Cancer | |||
| 36 | Signaling Pathways in Glioblastoma | |||
| 37 | TSLP Signaling Pathway | |||
| 38 | IL17 signaling pathway | |||
| 39 | IL-7 Signaling Pathway | |||
| 40 | Regulation of Microtubule Cytoskeleton | |||
| 41 | TWEAK Signaling Pathway | |||
| 42 | FSH signaling pathway | |||
| 43 | Leptin signaling pathway | |||
| 44 | TSH signaling pathway | |||
| 45 | RANKL/RANK Signaling Pathway | |||
| 46 | Integrated Breast Cancer Pathway | |||
| 47 | SREBP signalling | |||
| 48 | Integrated Cancer pathway | |||
| 49 | IL-1 signaling pathway | |||
| 50 | Metabolism of nitric oxide | |||
| 51 | Integrin-mediated Cell Adhesion | |||
| 52 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
| 53 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 54 | Angiogenesis | |||
| 55 | TOR Signaling | |||
| 56 | Regulation of toll-like receptor signaling pathway | |||
| 57 | AMPK Signaling | |||
| 58 | Androgen receptor signaling pathway | |||
| 59 | IL-5 Signaling Pathway | |||
| 60 | Oxidative Stress | |||
| 61 | Transcriptional activation by NRF2 | |||
| 62 | NRF2 pathway | |||
| 63 | Nuclear Receptors Meta-Pathway | |||
| 64 | Aryl Hydrocarbon Receptor Pathway | |||
| 65 | Mesodermal Commitment Pathway | |||
| 66 | Aryl Hydrocarbon Receptor | |||
| 67 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
| 68 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
| 69 | Fatty Acid Biosynthesis | |||
| 70 | Liver X Receptor Pathway | |||
| 71 | Activation of Gene Expression by SREBP (SREBF) | |||
| 72 | SREBF and miR33 in cholesterol and lipid homeostasis | |||
| 73 | Metabolism of water-soluble vitamins and cofactors | |||
| 74 | Integration of energy metabolism | |||
| 75 | Fatty acid, triacylglycerol, and ketone body metabolism | |||
| 76 | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| 77 | Differentiation of white and brown adipocyte | |||
| 78 | Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||
| 79 | Transcriptional Regulation of White Adipocyte Differentiation | |||
| 80 | Adipogenesis | |||
| 81 | Nuclear Receptors | |||
| 82 | SIDS Susceptibility Pathways | |||
| 83 | TGF Beta Signaling Pathway | |||
| 84 | Apoptosis Modulation by HSP70 | |||
| 85 | MAPK Signaling Pathway | |||
| 86 | Myometrial Relaxation and Contraction Pathways | |||
| 87 | IL1 and megakaryotyces in obesity | |||
| 88 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| 89 | Hair Follicle Development: Organogenesis (Part 2 of 3) | |||
| 90 | Hair Follicle Development: Induction (Part 1 of 3) | |||
| 91 | Selenium Metabolism and Selenoproteins | |||
| 92 | Cytosolic sensors of pathogen-associated DNA | |||
| 93 | Fc epsilon receptor (FCERI) signaling | |||
| 94 | Signaling by the B Cell Receptor (BCR) | |||
| 95 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
| 96 | Structural Pathway of Interleukin 1 (IL-1) | |||
| 97 | EBV LMP1 signaling | |||
| 98 | Neural Crest Differentiation | |||
| 99 | Signalling by NGF | |||
| 100 | TCR signaling | |||
| 101 | RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | |||
| 102 | Interleukin-1 signaling | |||
| 103 | Interleukin-1 processing | |||
| 104 | Apoptosis Modulation and Signaling | |||
| 105 | Folate Metabolism | |||
| 106 | Vitamin B12 Metabolism | |||
| 107 | Selenium Micronutrient Network | |||
| 108 | Osteopontin Signaling | |||